|Public (LSE: VEC)|
Bruno Angelici, Chairman|
James Ward-Lilley, (CEO)
|Revenue||£72.0 million (2016)|
|£(5.1) million (2016)|
|£5.0 million (2016)|
The company was formed in 1997 as a start-up pharmaceuticals business. In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies. In 2004 it was listed on the Alternative Investment Market. In 2007 it acquired Innovata plc, another developer of pulmonary products, and then moved on the full list of the London Stock Exchange. It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014. On 10 June 2016 Vectura completed a merger with Skyepharma; the merged company will continue to be known as Vectura.
The Group is a developer of inhaled therapies for the treatment of respiratory diseases.
- "Annual Report 2015/16" (PDF). Vectura Group. Retrieved 24 November 2016.
- "History". Vectura Group. Retrieved 3 August 2016.
- Vectura buys Innovata Guardian, 17 November 2006
- "UK's Vectura buys Activaero for £108 million". Pharma Times. 16 March 2014. Retrieved 20 June 2015.
- "Vectura and Skyepharma to merge in £441m deal". The Telegraph. 16 March 2016. Retrieved 11 June 2016.
- "Dr Karl Keegan to join Vectura Group". Manufacturing chemist. Retrieved 20 June 2015.